

## Erratum

### Correction to:

Rothermundt C, et al. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). *Swiss Med Wkly.* 2018;148:w14640. DOI: <https://doi.org/10.4414/smw.2018.14640>

### Affiliation

Dr Silke Gillessen's second affiliation has been added:  
<sup>a</sup> Klinik für Medizinische Onkologie und Hämatologie, Departement Innere Medizin, Kantonsspital St. Gallen, Switzerland

### Wording

All references to “non-seminoma tumour(s)” are now “non-seminoma(s)”.

### Summary: Results

The interquartile ranges for tumour size are reported separately for the two tumour types: 2.5–5.0 and 2.3–4.5 cm for seminomas and non-seminomas, respectively. The number of patients who did not receive therapy that conformed with guidelines was 11 (not 5).

### Results: Tumour markers and stage of disease

In stage III seminoma, 72.7% of patients had marker-positive disease (not 66.7%).

### Results: Table 4

For the patients with stage III seminoma, the percentages reported for each treatment regimen are the proportion of the prognosis group (not the treatment type).

### Discussion

Any tumour marker was elevated in non-seminoma stage I in 64.9% (not 64.5%) of patients.